New drug combo after transplant shows promise against returning cancers
NCT ID NCT02681302
First seen Apr 10, 2026 · Last updated May 11, 2026 · Updated 2 times
Summary
This study tested a combination of two immunotherapy drugs (nivolumab and ipilimumab) given after a stem cell transplant in people with high-risk multiple myeloma or lymphoma. The goal was to see if this approach is safe and can help prevent the cancer from coming back. The study included 46 participants and was stopped early.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hackensack University medical Center
Hackensack, New Jersey, 07601, United States
-
Lombardi Comprehensive Cancer Center at Georgetown University Medical Center
Washington D.C., District of Columbia, 20007, United States
Conditions
Explore the condition pages connected to this study.